Transcription of TIMP3, DAPK1, and AKR1B10 in squamous-cell lung cancer

Tamara D. Mashkova(Engelhardt Institute of Molecular Biology), Lev L. Kisselev(Engelhardt Institute of Molecular Biology), Е. П. Копанцев(Russian Academy of Sciences), О. Л. Зиновьева(Engelhardt Institute of Molecular Biology), М В Зиновьева(Russian Academy of Sciences), E. D. Sverdlov(Russian Academy of Sciences), Ekaterina S. Kropotova(Engelhardt Institute of Molecular Biology), T. V. Vinogradova(Russian Academy of Sciences), К. К. Лактионов(Russian Cancer Research Center NN Blokhin), М. В. Фридман(New York University), I. B. Zborovskaya(Russian Cancer Research Center NN Blokhin), N. Yu. Oparina(Engelhardt Institute of Molecular Biology), V. I. Dubovaya(Engelhardt Institute of Molecular Biology), А. Б. Полтараус(Engelhardt Institute of Molecular Biology), O. T. Kasymova(Russian Cancer Research Center NN Blokhin)
Molecular Biology
December 1, 2006
10.1134/s0026893306060148
Cited by 28

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
|Journal of Clinical Oncology|2022|334